After finishing at $20.64 in the prior trading day, Macrogenics Inc (NASDAQ: MGNX) closed at $21.47, up 4.02%. In other words, the price has increased by $+0.83 from its previous closing price. On the day, 1728943 shares were traded. MGNX stock price reached its highest trading level at $21.88 during the session, while it also had its lowest trading level at $20.66.
Ratios:
Our goal is to gain a better understanding of MGNX by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 5.66 and its Current Ratio is at 5.68. In the meantime, Its Debt-to-Equity ratio is 0.18 whereas as Long-Term Debt/Eq ratio is at 0.16.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, BTIG Research on March 04, 2024, Reiterated its Buy rating but revised its target price to $24 from $12 previously.
On February 14, 2024, H.C. Wainwright Downgraded its rating to Neutral which previously was Buy and also upped its target price recommendation from $12 to $14.
Citigroup Upgraded its Neutral to Buy on December 20, 2023, whereas the target price for the stock was revised from $7 to $13.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Mar 04 ’24 when Risser Eric Blasius sold 41,159 shares for $19.76 per share. The transaction valued at 813,501 led to the insider holds 38,900 shares of the business.
Karrels James sold 30,000 shares of MGNX for $615,000 on Mar 04 ’24. The SVP, CFO and Secretary now owns 171,452 shares after completing the transaction at $20.50 per share. On Mar 04 ’24, another insider, Spitznagel Thomas, who serves as the Sr VP, Technical Ops of the company, sold 10,000 shares for $20.00 each. As a result, the insider received 200,000 and left with 8,316 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, MGNX now has a Market Capitalization of 1.28B and an Enterprise Value of 1.06B. As of this moment, Macrogenics’s Price-to-Earnings (P/E) ratio for their current fiscal year is 26.92. For the stock, the TTM Price-to-Sale (P/S) ratio is 10.99 while its Price-to-Book (P/B) ratio in mrq is 6.87. Its current Enterprise Value per Revenue stands at 7.04 whereas that against EBITDA is 55.52.
Stock Price History:
Over the past 52 weeks, MGNX has reached a high of $21.33, while it has fallen to a 52-week low of $4.29. The 50-Day Moving Average of the stock is 14.09, while the 200-Day Moving Average is calculated to be 7.78.
Shares Statistics:
The stock has traded on average 1.11M shares per day over the past 3-months and 1.64M shares per day over the last 10 days, according to various share statistics. A total of 61.70M shares are outstanding, with a floating share count of 58.12M. Insiders hold about 6.30% of the company’s shares, while institutions hold 96.03% stake in the company. Shares short for MGNX as of Feb 15, 2024 were 6.38M with a Short Ratio of 5.76, compared to 7.93M on Jan 12, 2024. Therefore, it implies a Short% of Shares Outstanding of 10.29% and a Short% of Float of 12.56%.
Earnings Estimates
Its stock is currently analyzed by 10 different market analysts. On average, analysts expect EPS of -$0.15 for the current quarter, with a high estimate of $0.38 and a low estimate of -$0.37, while EPS last year was $0.21. The consensus estimate for the next quarter is -$0.49, with high estimates of -$0.31 and low estimates of -$0.62.
Analysts are recommending an EPS of between $0.7 and $0.22 for the fiscal current year, implying an average EPS of $0.37. EPS for the following year is -$1.81, with 10 analysts recommending between -$1.03 and -$2.49.
Revenue Estimates
10 analysts predict $31.87M in revenue for the current quarter. It ranges from a high estimate of $72.4M to a low estimate of $14.46M. As of the current estimate, Macrogenics Inc’s year-ago sales were $73.1M, an estimated decrease of -56.40% from the year-ago figure. For the next quarter, 7 analysts are estimating revenue of $14.36M, a decrease of -41.40% over than the figure of -$56.40% in the same quarter last year. There is a high estimate of $22.7M for the next quarter, whereas the lowest estimate is $10.46M.
A total of 10 analysts have provided revenue estimates for MGNX’s current fiscal year. The highest revenue estimate was $120.4M, while the lowest revenue estimate was $62.49M, resulting in an average revenue estimate of $80.1M. In the same quarter a year ago, actual revenue was $151.94M, down -47.30% from the average estimate. Based on 10 analysts’ estimates, the company’s revenue will be $82.86M in the next fiscal year. The high estimate is $137.34M and the low estimate is $42.47M. The average revenue growth estimate for next year is up 3.40% from the average revenue estimate for this year.
